Is retatrutide safe? What the trials reported

Reviewed 17 sourcesPublished by PepVault

Is retatrutide safe? What its trials counted of pancreatitis, gallbladder and heart events, low blood sugar and deaths, who was left out, and what is unknown.

A man in a navy tank top holding a steel bottle on a clifftop path above the sea
Last reviewed
Sources
17
Questions
9
Compounds
2

The short answer

Retatrutide is not approved anywhere yet. Its trial papers and Lilly describe its safety as consistent with the GLP-1 drug class: mostly stomach side effects, rare pancreatitis and gallbladder cases, no severe low blood sugar in the diabetes trials, deaths judged unrelated, and no clear heart-event difference from placebo in people with heart disease. Data run two years; the FDA calls off-trial products of unknown quality.

  • Phase 2 registry results: 3 pancreatitis and 2 gallbladder cases among 457 people on retatrutide, none among 115 on placebo.
  • TRIUMPH-3, adults with heart disease: 44 vs 52 major heart events on retatrutide vs placebo, no clear difference either way.
  • No severe low blood sugar in the diabetes trials that report it; investigators judged the phase 3 deaths unrelated to the drug.
  • Not approved anywhere as of November 2026; the FDA calls retatrutide sold 'for research purposes' of unknown quality.

Every number checked at its primary source · · 17 sources · How we research

Evidence: Randomised phase 2 and phase 3 trials in people, all sponsored by Eli Lilly (NEJM, The Lancet, registry results); the phase 3 heart-event and several safety figures come from Lilly's company releases, and the off-trial evidence is two case reports.

A man in a navy tank top holding a steel bottle on a clifftop path above the sea

Is retatrutide safe in the trials so far?

So far, the trial reports say it behaves like the drug class it belongs to. Retatrutide switches on three hormone receptors at once: GLP-1, GIP and glucagon1. The two largest published phase 3 trials put their verdicts plainly. TRIUMPH-2, 1,152 adults with obesity and type 2 diabetes for 80 weeks, found 'a safety profile generally consistent with other molecules with GLP-1 receptor agonism'2. TRANSCEND-T2D-1, 537 adults with type 2 diabetes for 40 weeks, found an adverse event profile consistent with the same class3. Lilly says the same of TRIUMPH-1, its 2,339-person obesity trial: the types of adverse events were generally consistent with other incretin-based drugs8.

That covers the side effects people feel most, the nausea, diarrhoea and skin tingling, which PepVault's guide to retatrutide side effects lays out trial by trial. This guide is about the rest of the safety question: the rare serious events, who the trials left out, and what the trials cannot show yet.

PepVault's side-effect log keeps each symptom with its date, the compound, a severity from minimal to very severe and a note, and the doctor's report puts them in one document beside your logged doses, so a clinician can see what happened and when. Log it in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's side-effect log keeps each symptom with its date, the compound, a severity from minimal to very severe and a note, and the doctor's report puts them in one document beside your logged doses, so a clinician can see what happened and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Did anyone get pancreatitis or gallbladder problems on retatrutide?

A handful of people. The two phase 2 trials, one in obesity and one in type 2 diabetes45, posted every serious adverse event to ClinicalTrials.gov, the federal trial registry. A serious adverse event is, for example, one that puts someone in hospital, threatens life or ends it, whatever the cause. Here is what they counted67:

Serious eventObesity trial: retatrutide (267)Obesity trial: placebo (70)Diabetes trial: retatrutide (190)Diabetes trial: placebo (45)
Acute pancreatitis1020
Gallbladder inflammation (cholecystitis)1010
Atrial fibrillation (irregular heartbeat)0010
Heart failure1020
Deaths1000
Anyone with a serious event10 (3.7%)3 (4.3%)11 (5.8%)3 (6.7%)

The obesity trial counted events for up to 52 weeks and the diabetes trial for up to 280 days67. The diabetes trial's two pancreatitis cases came on the 0.5 mg dose and on 8 mg, not the top dose7. With groups this small, single cases can't give a rate. The phase 3 abstracts and Lilly's releases give no pancreatitis or gallbladder counts12389, and no phase 3 trial has posted results to the registry yet, so those counts sit in the full papers' safety tables.

Both events are known for the approved drugs too. Zepbound's label lists acute gallbladder disease and acute pancreatitis among its warnings. In its weight-loss trials, gallbladder inflammation was reported in 0.7% on tirzepatide against 0.2% on placebo, and the label says acute gallbladder events were associated with weight reduction14. Retatrutide's phase 3 trials did not enrol anyone who had had pancreatitis1112.

Has anyone died taking retatrutide?

A few people died during the trials, and in the two phase 3 trials that report deaths, investigators judged none related to the drug. In TRIUMPH-2, two people died on 4 mg, three on 9 mg, one on 12 mg and one on placebo, and all deaths were deemed unrelated to the study drug by the investigator2. In TRANSCEND-T2D-1, two people died, both on 4 mg, both unrelated3. The phase 2 obesity trial recorded one death, a drowning6, and the phase 2 diabetes trial none5.

Large trials that run for a year or more expect some deaths from ordinary causes; that is why a placebo group is there. The count to watch is the gap between groups. In TRIUMPH-2, each retatrutide dose group had one to three deaths against one on placebo, numbers too small to show a pattern either way, and the investigators judged every one unrelated2.

Does retatrutide cause heart problems?

Not so far, in the one finished trial of people with heart disease. TRIUMPH-3 randomised 1,949 adults (the registry lists 1,946) with severe obesity and established cardiovascular disease, meaning a past heart attack, stroke or narrowed leg arteries that cause symptoms, for 80 weeks; half got retatrutide 9 or 12 mg and half placebo9. Its main goal was weight loss, and Lilly also counted major adverse cardiovascular events (MACE), the heart-attack-and-stroke tally regulators use, in analyses planned in advance9:

Heart events in TRIUMPH-3Retatrutide 9 and 12 mgPlaceboHazard ratio (95% CI)
MACE-5: death from any cause, heart attack, stroke, heart failure event or a procedure to reopen a heart artery44520.82 (0.55 to 1.22)
MACE-3: heart death, heart attack or stroke27231.12 (0.64 to 1.96)

A hazard ratio below 1 means fewer events on the drug. Both ranges cross 1, so neither result shows a difference either way; events were also rarer than Lilly expected in both groups9. Along the way the top dose cut systolic blood pressure by 9.3 mmHg and triglycerides by 37.0%9. The resting heart rate rises in the first months and eases after; the side-effects guide gives that timeline.

The trial that settles it is TRIUMPH-Outcomes: about 10,000 adults aged 45 or older with obesity and artery or kidney disease, built to measure heart and kidney outcomes, expected to finish in February 202913.

Can retatrutide cause low blood sugar?

Not on its own, in the trials. The phase 2 diabetes trial reported no severe hypoglycaemia5, and neither did TRANSCEND-T2D-1, where retatrutide was the only diabetes drug3. In TRIUMPH-3, high blood sugar was the side effect that ran the other way: 3.9% and 3.1% on retatrutide against 13.4% on placebo9.

The risk changes with company. Zepbound's label warns that low blood sugar is more likely when it is used with insulin or a sulfonylurea, and says lowering the dose of those drugs may lower the risk14. That is a prescriber's adjustment to make, not a reason to stop either drug alone.

Does the thyroid cancer warning apply to retatrutide?

Not formally, because retatrutide has no label yet; its trials treated the risk as if it did. Zepbound's label opens with a boxed warning, the FDA's strongest label warning: in rats, tirzepatide causes thyroid C-cell tumours, and it is unknown whether it does in humans14. The label rules it out for anyone with a personal or family history of medullary thyroid carcinoma (MTC), or with multiple endocrine neoplasia type 2 (MEN 2), an inherited condition14.

Retatrutide's phase 3 trials excluded exactly those people1112. Whether its future label carries the same box is the FDA's call at review. Until then, the rat finding is a warning the approved drugs in this class carry, and the label says its relevance to people has not been determined14.

Who was left out of the retatrutide trials?

The trial numbers describe adults who passed these screens, so they say little about anyone outside them. From the registry records of TRIUMPH-1 and TRANSCEND-T2D-11112:

  • Anyone under 18.
  • Anyone who had had pancreatitis.
  • Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
  • People with type 1 diabetes.
  • Anyone who had taken a weight-loss drug in the 90 days before screening, or had weight-loss surgery.
  • In TRANSCEND-T2D-1 also: a heart attack, stroke or heart-failure hospital stay in the past 90 days, the most severe heart failure, active cancer or remission under five years, any past suicide attempt, severe low blood sugar in the past six months, very low kidney function and known stomach-emptying problems.

One of these groups, people with type 1 diabetes, has since turned up in a medical journal using retatrutide from outside the trials; the last section covers it.

What is still unknown about retatrutide's safety?

  • Use past two years. The longest data are TRIUMPH-1's extension to 104 weeks8. Obesity drugs are often taken for years.
  • Rare events. The first TRIUMPH programme enrolled more than 5,800 people9. A side effect that hits 1 in 10,000 can hide in numbers like that; it surfaces after approval, when far more people take a drug.
  • Heart and kidney outcomes. TRIUMPH-Outcomes reads out in 202913.
  • The full safety tables. TRIUMPH-3's heart-event figures come from Lilly's release so far, not a peer-reviewed paper9, and the phase 3 registry records carry no posted results yet1112.
  • Approval. As of November 2026 retatrutide is not approved by the FDA or any regulator anywhere, and Lilly plans to file with the FDA in the first quarter of 2027910.

Is retatrutide sold online the same as the trial drug?

No, and every trial number above belongs to Lilly's drug alone. The FDA's statement, current as of October 1, 2026, is direct: retatrutide cannot be used in compounding under federal law, is not a component of any approved drug, and has not been found safe and effective for any condition15. The agency has warned telehealth companies for marketing it, ingredient distributors for selling it to compounders, and companies selling it labelled 'for research purposes' or 'not for human consumption', products it calls 'of unknown quality'15. Lilly states that anyone selling retatrutide to consumers is breaking the law10.

The journals now carry the first cases. A woman in her mid-20s had five days of nausea and vomiting after four weekly injections of an unverified product, given by a self-described life coach with no medical qualification; it resolved within a week16. A man with type 1 diabetes, one of the groups the trials excluded, was admitted with vomiting, rising ketones and later repeated low blood sugar after an online product, with a gut infection (Shigella) at the same time, so the case cannot say which caused what17. Single cases prove no rate; they show what the trial numbers don't cover. The legal side, by agency, is at pepvault.app/peptides/retatrutide/legal-status.

When to get help Belly pain that is severe and does not ease, sometimes spreading to the back, upper belly pain with a fever or yellowing skin or eyes, or vomiting that stops you keeping fluids down is a reason to get medical care the same day14.

Track it in the app

Sources

  1. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
  2. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
  3. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. PubMed 42250575
  4. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
  5. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PubMed 37385280
  6. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Results record: serious adverse events and deaths. clinicaltrials.gov
  7. ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Results record: serious adverse events and deaths. clinicaltrials.gov
  8. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. prnewswire.com
  9. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3). Press release, July 23, 2026. prnewswire.com
  10. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, Oct 28, 2026. prnewswire.com
  11. ClinicalTrials.gov NCT05929066 (TRIUMPH-1). A study of retatrutide (LY3437943) in participants who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. clinicaltrials.gov
  12. ClinicalTrials.gov NCT06354660 (TRANSCEND-T2D-1). Effect of retatrutide compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. clinicaltrials.gov
  13. ClinicalTrials.gov NCT06383390 (TRIUMPH-Outcomes). The effect of retatrutide once weekly on cardiovascular outcomes and kidney outcomes in adults living with obesity (phase 3; sponsor Eli Lilly and Company). Record updated Oct 8, 2026. clinicaltrials.gov
  14. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information: boxed warning and warnings and precautions. DailyMed, version 40, August 2026. dailymed.nlm.nih.gov
  15. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
  16. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Rep. 2026. PubMed 42843917
  17. Branine N. Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes and concurrent Shigella gastroenteritis. Cureus. 2026. PubMed 42669023

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo